Antihypertensive and metabolic effects of empagliflozin in Ren-2 transgenic rats, an experimental non-diabetic model of hypertension
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F21%3A00081692" target="_blank" >RIV/00023001:_____/21:00081692 - isvavai.cz</a>
Alternative codes found
RIV/67985823:_____/21:00547427 RIV/00216208:11120/21:43922251
Result on the web
<a href="https://reader.elsevier.com/reader/sd/pii/S0753332221010301?token=D894D90F533E3886C68793239E1816539C9B619CB6168D0281C5A4AF263C4AFBDD159AD0524D0F27A4091AA4551F2990&originRegion=eu-west-1&originCreation=20211103115157" target="_blank" >https://reader.elsevier.com/reader/sd/pii/S0753332221010301?token=D894D90F533E3886C68793239E1816539C9B619CB6168D0281C5A4AF263C4AFBDD159AD0524D0F27A4091AA4551F2990&originRegion=eu-west-1&originCreation=20211103115157</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.biopha.2021.112246" target="_blank" >10.1016/j.biopha.2021.112246</a>
Alternative languages
Result language
angličtina
Original language name
Antihypertensive and metabolic effects of empagliflozin in Ren-2 transgenic rats, an experimental non-diabetic model of hypertension
Original language description
The new antidiabetic drugs, gliflozins, inhibit sodium-glucose transporter-2 in renal proximal tubules promoting glucose and sodium excretion. This leads not only to a significant improvement of glucose control but also to the reduction of blood pressure and body weight in both diabetic patients and experimental models. We examined whether these beneficial effects can also be achieved in a non-diabetic hypertensive model, namely in Ren-2 transgenic rats (TGR). Adult 6-month-old hypertensive TGR and their normotensive controls (Hannover Sprague-Dawley rats), were either untreated or treated with empagliflozin (10 mg/kg/day) for two months. Telemetric blood pressure monitoring, renal parameters as well as cardiac function via echocardiography were analyzed during the experiment. At the end of the study, the contribution of major vasoactive systems to blood pressure maintenance was studied. Metabolic parameters and markers of oxidative stress and inflammation were also analyzed. Empagliflozin had no effect on plasma glucose level but partially reduced blood pressure in TGR. Although food consumption was substantially higher in empagliflozin-treated TGR compared to the untreated animals, their body weight and the amount of epididymal and perirenal fat was decreased. Empagliflozin had no effect on proteinuria, but it decreased plasma urea, attenuated renal oxidative stress and temporarily increased urinary urea excretion. Several metabolic (hepatic triglycerides, non-esterified fatty acids, insulin) and inflammatory (TNF-alpha, leptin) parameters were also improved by empagliflozin treatment. By contrast, echocardiography did not reveal any effect of empagliflozin on cardiac function. In conclusion, empagliflozin exerted beneficial antihypertensive, anti-inflammatory and metabolic effects also in a non-diabetic hypertensive model.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30104 - Pharmacology and pharmacy
Result continuities
Project
<a href="/en/project/GA19-06199S" target="_blank" >GA19-06199S: Complex analysis of protective actions of empagliflozin on metabolic parameters and cardiorenal damage in experimental non-diabetic hypertension</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Biomedicine and pharmacotherapy
ISSN
0753-3322
e-ISSN
—
Volume of the periodical
144
Issue of the periodical within the volume
December
Country of publishing house
FR - FRANCE
Number of pages
11
Pages from-to
"art. no. 112246"
UT code for WoS article
000704894600003
EID of the result in the Scopus database
2-s2.0-85117067903